Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
-
The discovery of acetylsalicylic acid aspirin in paved
2024-05-13
The discovery of acetylsalicylic AK-7 (aspirin) in 1897 paved the way for the development of classical NSAIDs as first-line therapeutics for anti-inflammatory, anti-pyretic and analgesic therapy. Large efforts have been made in the following decades to improve the efficacy and in particular safety
-
Inhibitors of mPGES are considered
2024-05-13
Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e
-
br Conclusion There have been multiple clinical trials and
2024-05-13
Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi
-
Aurora A or B selective and pan
2024-05-13
Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas
-
Many ruthenium complexes were tested as
2024-05-13
Many ruthenium complexes were tested as potential anticancer agents and two complexes, namely NAMI-A (trans-[imH] [RuCl4(dmso-S)(im)]; im, imidazole) and KP1019 (trans-[indH][RuCl4(ind)2]; ind, indazole) have successfully entered clinical trials [27], [28]. NAMI-A is selectively active against metas
-
A positive correlation between nasopharyngeal CCL and CCL
2024-05-13
A positive correlation between nasopharyngeal CCL3 and CCL5 [16] concentrations and illness severity was shown in evaluating patients with RSV bronchiolitis [17]. CCL5 and CCL3 are important for monocyte and lymphocyte recruitment to the lung during RSV infection [7], [16], [18]. Despite the signifi
-
As the effects of baclofen on primary
2024-05-11
As the effects of baclofen on primary afferent activity are not reproduced by GABAA receptor agonists like muscimol and isoguvacine, this ionotropic receptor may play minimal role in the modulation of primary afferent activity. However, it is important to note that post-synaptic GABAA receptors rema
-
i am g To elucidate whether membrane fluidity changes
2024-05-11
To elucidate whether membrane fluidity changes could impact on signaling pathways, we examined the effects of Rh2 on the activation of Akt, a lipid raft-associated protein kinase, which promotes cell survival and blocks the apoptotic pathways. Upon pretreatment with 5 mM MβCD and in the absence of R
-
Several combination studies have been performed using animal
2024-05-11
Several combination studies have been performed using animal models of mucormycosis, principally involving R. arrhizus. In two investigations using diabetic and/or neutropenic mice, a combination of a polyene with an echinocandin was shown to improve survival compared with monotherapies [25], [34].
-
br Eprosartan The AT R antagonist eprosartan is approved
2024-05-11
Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential Glycopyrrolate and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events,
-
A candidate protein for the regulation
2024-05-11
A candidate protein for the regulation of AMPAR transport is CaMKII, a Ca2+-dependent kinase with diverse cellular functions. With respect to synaptic transmission, CaMKII is recognized as a key synaptic protein that is required to modify the number of synaptic AMPARs in response to LTP and LTD stim
-
br Perspective AA LA and
2024-05-11
Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
-
Therefore to better understand the functional properties of
2024-05-11
Therefore, to better understand the functional properties of Peruvian infusion tea plants and provide evidence for the development of functional food supplements containing the Peruvian infusion tea plant, the aldose reductase inhibition together with the antioxidant activities of 24 selected Peruvi
-
The inflammatory cytokine IL is an
2024-05-11
The inflammatory cytokine IL-6 is an additional factor that has been hypothesized to contribute to epinephrine-mediated repression of drug detoxifying proteins such as CYP3A4 (Aninat et al., 2008). Indeed, this CYP is well-known to be repressed by IL-6 (Dickmann et al., 2011) and epinephrine has pre
-
Circulating adrenal derived stress hormones
2024-05-11
Circulating adrenal-derived stress hormones, epinephrine and corticosterone mediate their tissue effects through adrenergic (AR; α and β) and glucocorticoid (GR) receptors. AR are widely distributed throughout the body and although epinephrine is a prototypical agonist for all types of AR, the selec
13822 records 6/922 page Previous Next First page 上5页 678910 下5页 Last page